SCHEDULE 13G/A: Stonepine Capital Entities Disclose 3.8% Stake in Inovio Pharmaceuticals
Beneficial Ownership Report
Stonepine Capital Management, LLC and its affiliated entities have filed an amended Schedule 13G, disclosing a beneficial ownership of 3.8% of Inovio Pharmaceuticals, Inc.'s common stock as of March 31, 2025.
Summary
- Stonepine Capital Management, LLC, Stonepine Capital, L.P., Stonepine GP, LLC, and Jon M. Plexico jointly reported beneficial ownership of 1,434,997 shares of Inovio Pharmaceuticals, Inc. Common Stock.
- This aggregate amount represents 3.8% of Inovio Pharmaceuticals' outstanding Common Stock.
- The ownership includes 518,331 shares of Common Stock directly owned and 916,666 shares underlying warrants.
- The percentage is calculated based on 36,667,221 shares of Common Stock outstanding as of March 12, 2025, as reported in Inovio's Form 10-K for the fiscal year ended December 31, 2024.
- The reporting persons share both voting and dispositive power over all 1,434,997 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Inovio Pharmaceuticals, Inc.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain subjective language or forward-looking statements that would indicate a positive or negative sentiment. It is a neutral regulatory filing.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a passive investment stake by an investment firm in a publicly traded biotechnology company. It does not provide specific insights into broader industry trends or Inovio's competitive position beyond the fact of the investment.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant, though passive, ownership stake by Stonepine Capital entities, which may be of interest to other investors.
Key Dates
| Date | Description |
|---|---|
| 2024-12-31 | Fiscal year end for Inovio Pharmaceuticals, Inc., as reported in their Form 10-K, which provided the basis for outstanding shares. |
| 2025-03-12 | Date on which 36,667,221 shares of Inovio Pharmaceuticals Common Stock were reported as outstanding in the Issuer's Form 10-K. |
| 2025-03-31 | Date of event which requires the filing of this Schedule 13G statement, indicating the beneficial ownership position. |
| 2025-05-13 | Date of the Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G. |
| 2025-05-14 | Date the Schedule 13G Amendment No. 1 was signed and filed. |
Keywords
Inovio Pharmaceuticals, Stonepine Capital Management, Beneficial Ownership, Schedule 13G, Common Stock, Investment Adviser, Warrants, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.